According to filings with the U.S. Securities and Exchange Commission, Linnaeus Therapeutics is raising up to $10,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Linnaeus Therapeutics
Linnaeus Therapeutics aims to turn real-world human biology into medicines that restore resilience against cancer, cardiometabolic diseases, and aging. We start from observed sex differences to identify mechanisms like GPER activation that link tumor suppression, vascular health, metabolism, and brain function. Our mission is not only to develop GPER-targeted therapies, but also to advance and openly share the tools, data, and measures that define how these interventions change the trajectory of aging.

To learn more about Linnaeus Therapeutics, visit https://linnaeustx.com/
Linnaeus Therapeutics Linkedin Page: https://www.linkedin.com/company/linnaeustx/

Contact:
Patrick Mooney, Chief Executive Officer
856-433-1500
https://www.linkedin.com/in/patrick-mooney-5336093/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.